Cancer, Malaria & TB Vaccines

Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovaleP. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease, HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.

    Related Conference of Cancer, Malaria & TB Vaccines

    November 19-20, 2025

    6th International Conference on Vaccine Research

    Tokyo, Japan
    December 22-23, 2025

    7th World Congress on Vaccine and Immunology

    Amsterdam, Netherlands
    September 21-22, 2026

    44th Euro Global Summit and Expo on Vaccines & Vaccination

    Barcelona, Spain

    Cancer, Malaria & TB Vaccines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in